annual EBITDA:
$255.74M+$346.08M(+383.08%)Summary
- As of today (September 16, 2025), PTGX annual EBITDA is $255.74 million, with the most recent change of +$346.08 million (+383.08%) on December 31, 2024.
- During the last 3 years, PTGX annual EBITDA has risen by +$378.81 million (+307.80%).
- PTGX annual EBITDA is now at all-time high.
Performance
PTGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$40.60M-$21.53M(-112.89%)Summary
- As of today (September 16, 2025), PTGX quarterly EBITDA is -$40.60 million, with the most recent change of -$21.53 million (-112.89%) on June 30, 2025.
- Over the past year, PTGX quarterly EBITDA has dropped by -$3.28 million (-8.80%).
- PTGX quarterly EBITDA is now -119.66% below its all-time high of $206.54 million, reached on March 31, 2024.
Performance
PTGX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$26.84M-$3.28M(-10.90%)Summary
- As of today (September 16, 2025), PTGX TTM EBITDA is $26.84 million, with the most recent change of -$3.28 million (-10.90%) on June 30, 2025.
- Over the past year, PTGX TTM EBITDA has dropped by -$128.77 million (-82.75%).
- PTGX TTM EBITDA is now -89.51% below its all-time high of $255.74 million, reached on December 31, 2024.
Performance
PTGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PTGX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +383.1% | -8.8% | -82.8% |
| 3 y3 years | +307.8% | 0.0% | +120.6% |
| 5 y5 years | +440.1% | -132.8% | +139.4% |
PTGX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +299.8% | -119.7% | +2.3% | -89.5% | +117.9% |
| 5 y | 5-year | at high | +299.8% | -119.7% | +2.3% | -89.5% | +117.9% |
| alltime | all time | at high | +299.8% | -119.7% | +2.3% | -89.5% | +117.9% |
PTGX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$40.60M(+112.9%) | $26.84M(-10.9%) |
| Mar 2025 | - | -$19.07M(-115.0%) | $30.12M(-88.2%) |
| Dec 2024 | $255.74M(-383.1%) | $127.32M(-412.0%) | $255.74M(+67.9%) |
| Sep 2024 | - | -$40.81M(+9.3%) | $152.30M(-2.1%) |
| Jun 2024 | - | -$37.32M(-118.1%) | $155.61M(+2.8%) |
| Mar 2024 | - | $206.54M(+764.9%) | $151.39M(-267.6%) |
| Dec 2023 | -$90.34M(-29.4%) | $23.88M(-163.7%) | -$90.34M(-39.7%) |
| Sep 2023 | - | -$37.50M(-9.7%) | -$149.90M(+4.2%) |
| Jun 2023 | - | -$41.53M(+18.0%) | -$143.85M(+0.7%) |
| Mar 2023 | - | -$35.19M(-1.4%) | -$142.91M(+11.6%) |
| Dec 2022 | -$128.00M(+4.0%) | -$35.68M(+13.4%) | -$128.00M(-0.4%) |
| Sep 2022 | - | -$31.45M(-22.5%) | -$128.53M(-1.4%) |
| Jun 2022 | - | -$40.60M(+100.2%) | -$130.30M(+8.6%) |
| Mar 2022 | - | -$20.28M(-44.0%) | -$119.95M(-2.5%) |
| Dec 2021 | -$123.07M(+100.0%) | -$36.20M(+9.0%) | -$123.07M(+17.4%) |
| Sep 2021 | - | -$33.22M(+9.8%) | -$104.84M(+33.2%) |
| Jun 2021 | - | -$30.25M(+29.3%) | -$78.74M(+19.4%) |
| Mar 2021 | - | -$23.40M(+30.2%) | -$65.92M(+7.1%) |
| Dec 2020 | -$61.52M | -$17.97M(+152.4%) | -$61.52M(+3.7%) |
| Sep 2020 | - | -$7.12M(-59.2%) | -$59.36M(-12.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$17.44M(-8.2%) | -$68.11M(-15.8%) |
| Mar 2020 | - | -$19.00M(+20.3%) | -$80.86M(+7.5%) |
| Dec 2019 | -$75.19M(+91.8%) | -$15.80M(-0.5%) | -$75.19M(+4.2%) |
| Sep 2019 | - | -$15.87M(-47.4%) | -$72.12M(+10.1%) |
| Jun 2019 | - | -$30.18M(+126.4%) | -$65.49M(+47.6%) |
| Mar 2019 | - | -$13.33M(+4.7%) | -$44.38M(+13.2%) |
| Dec 2018 | -$39.20M(+7.2%) | -$12.74M(+37.9%) | -$39.20M(+35.6%) |
| Sep 2018 | - | -$9.24M(+1.9%) | -$28.91M(+17.8%) |
| Jun 2018 | - | -$9.07M(+11.3%) | -$24.55M(-19.6%) |
| Mar 2018 | - | -$8.15M(+231.9%) | -$30.52M(-16.5%) |
| Dec 2017 | -$36.55M(+13.0%) | -$2.46M(-49.6%) | -$36.55M(-19.5%) |
| Sep 2017 | - | -$4.87M(-67.6%) | -$45.42M(-4.6%) |
| Jun 2017 | - | -$15.04M(+6.0%) | -$47.60M(+20.3%) |
| Mar 2017 | - | -$14.19M(+25.3%) | -$39.57M(+22.3%) |
| Dec 2016 | -$32.35M(+122.4%) | -$11.32M(+60.5%) | -$32.35M(+24.7%) |
| Sep 2016 | - | -$7.05M(+0.7%) | -$25.94M(+37.4%) |
| Jun 2016 | - | -$7.00M(+0.5%) | -$18.89M(+59.0%) |
| Mar 2016 | - | -$6.97M(+41.8%) | -$11.88M(+57.5%) |
| Dec 2015 | -$14.55M(+60.5%) | -$4.91M(+86.8%) | -$7.54M(+186.8%) |
| Mar 2015 | - | -$2.63M | -$2.63M |
| Dec 2014 | -$9.06M | - | - |
FAQ
- What is Protagonist Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Protagonist Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Protagonist Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Protagonist Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of PTGX is $255.74M
What is the all time high annual EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high annual EBITDA is $255.74M
What is Protagonist Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, PTGX annual EBITDA has changed by +$346.08M (+383.08%)
What is Protagonist Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of PTGX is -$40.60M
What is the all time high quarterly EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high quarterly EBITDA is $206.54M
What is Protagonist Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, PTGX quarterly EBITDA has changed by -$3.28M (-8.80%)
What is Protagonist Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of PTGX is $26.84M
What is the all time high TTM EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high TTM EBITDA is $255.74M
What is Protagonist Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, PTGX TTM EBITDA has changed by -$128.77M (-82.75%)